This study is based on the medical and health systems of China and the US, which will provide a more accurate reference for doctors in China and the US to use Talazoparib in the treatment of BRCA1/2 type advanced breast cancer patients in the future, and Chinese medical insurance will provide drug economic support for negotiations on Talazoparib treatment of advanced breast cancer. The gene discussed is BRCA1; the disease is breast cancer.